EAACI Congress 2026: Advances in Allergy and Asthma Care

The European Academy of Allergy and Clinical Immunology (EAACI) concluded its 2026 annual congress in Istanbul, hosting 7,429 delegates from 110 countries to address the global burden of allergic diseases. The event centered on the “Vision Zero” initiative, which aims to eliminate the impact of asthma and allergies through precision medicine, digital health, and standardized clinical care.

Who is leading the EAACI for 2026–2028?

Professor Mohamed Shamji has officially assumed the presidency of the EAACI for the 2026–2028 term. He succeeds Professor María José Torres, who led the organization through a period of increased international collaboration and the initial rollout of the Vision Zero framework.

During his inaugural address, Professor Shamji emphasized a goal of creating a “truly global” academy. He plans to integrate research, clinical guidelines, and digital engagement into a single platform to accelerate medical breakthroughs. According to official statements from the EAACI, this leadership transition marks a strategic pivot toward a more interconnected ecosystem for researchers and clinicians worldwide.

What were the scientific highlights of the congress?

Researchers presented 2,420 scientific abstracts during the four-day event, covering advancements in immunology and patient-centered care. The presentations highlighted several core areas of focus:

* Precision Medicine: Tailoring immunotherapy treatments to individual patient profiles.
* Digital Innovation: Utilizing new technologies to monitor patient outcomes and adherence to treatment plans.
* Environmental Health: Addressing how climate change and environmental factors influence the prevalence of allergic reactions.
* Preventative Strategies: Strengthening early intervention programs to reduce the long-term progression of respiratory conditions.

The volume of research presented reflects a significant increase in data sharing compared to previous annual meetings, according to the organization’s reporting. By shifting the focus toward “Vision Zero,” the EAACI aims to translate these abstract findings into clinical practice more rapidly than in previous years.

Why does the Vision Zero initiative matter for patients?

The Vision Zero initiative is designed to address the rising global prevalence of allergic diseases, which currently affect hundreds of millions of people. By standardizing care across borders, the EAACI intends to ensure that patients receive consistent, evidence-based treatments regardless of their geographic location.

Professor Torres noted that the initiative remains the organization’s primary ambition. By aligning global health policies with updated clinical guidelines, the academy seeks to reduce the severity of symptoms and the frequency of asthma attacks in the patient population.

Summary of Key Developments

| Feature | Details |
| :— | :— |
| Attendance | 7,429 delegates |
| Global Reach | 110 countries represented |
| Research Output | 2,420 scientific abstracts |
| New President | Professor Mohamed Shamji (2026–2028) |
| Primary Goal | Vision Zero (Eliminating allergy and asthma burden) |

The congress served as a venue for establishing new partnerships between clinicians, industry leaders, and patient advocacy groups. These collaborations are expected to influence public health policies and medical research priorities through the end of the decade. As the new executive committee begins its term, the focus remains on closing the gap between laboratory discovery and patient-facing clinical care.